B-cell acute lymphoblastic leukaemia is an aggressive type of blood cancer that occurs because too many B-cell lymphoblasts (immature white blood cells) exist in the bone marrow and blood. It is the most common type of acute lymphoblastic leukemia (ALL). Note that B-cell ALL is also called B-cell acute lymphocytic leukaemia and precursor B-lymphoblastic leukaemia.
Disease: B-cell Acute Lymphoblastic Leukemia, ALL, (NCT03298828)
Principal Investigator: Xiaoyun Shang, Dr. Third Military Medical University
Third Military Medical University
B-cell Acute Lymphoblastic Leukemia Disease InformationB-cell Acute Lymphoblastic Leukemia FrequencyThe Role of Gene Editing Within CAR T-Cell Therapy Development - Interview with Professor Waseem QasimCAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Status: Active not recruiting
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells that are genetically modified to express a CD19-targting chimeric antigen receptor (CAR), and PD-1 knockout-engineered T cells in patients with relapsed or refractory B cell non-Hodgkin lymphoma lymphoma and leukaemia. Following informed consent and registration to the trial, patients will undergo an unstimulated leukapheresis to yield cells for generation of the CD19 CAR T-cells. Patients will receive the CD19 CAR and PD-1 knockout-engineered T-cells following lymphodepleting chemotherapy.Last updated: Apr. 8, 2022